Literature DB >> 22969922

Long-term efficacy of intermittent peritoneal dialysis using various doses.

Zhi-Yong Zhang1, Chun-Hua Zhou, Ming-Xu Li, Yong-Wu Yu.   

Abstract

The objective of the present study was to investigate the long-term clinical efficacy of intermittent peritoneal dialysis (IPD) using various doses and to explore the most suitable dialysis dose and practice pattern for patients. A total of 52 inpatients/outpatients who had undergone IPD for more than 5 years were recruited and divided into three groups according to the dialysis dose: 4 liters in Group A, 6 liters in Group B and 8 liters in Group C. The dwell time was 4 h. All patients were fasted overnight. The dialysis adequacy, nutritional status, complication control, blood pressure and intra-abdominal infection were determined and observed among these patients. Barthel index (BI) and Hamilton Depression Scale (HAMD) were employed to measure the activities of daily living (ADL) and degree of depression, respectively. The dialysis adequacy and ultrafiltration volume in Group A were lower than those in Groups B and C, but the residual urine volume was larger than that in the latter two groups. In addition, there was a marked difference in the control of complications between Group A and Groups B and C. When compared to Groups A and B, the nutritional status in Group C was significantly decreased, the mean arterial pressure and intra-abdominal infection rates were dramatically increased, and the HAMD scores were also higher (P<0.05). No significant difference was noted in the BI. For patients undergoing long-term IPD, individualized dialysis dose may benefit the dialysis adequacy, nutritional status, control of complications, blood pressure, rate of intra-abdominal infection, ADL and depression.

Entities:  

Year:  2011        PMID: 22969922      PMCID: PMC3438724          DOI: 10.3892/etm.2011.444

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  22 in total

Review 1.  Peritoneal dialysis in the 21st century: an analysis of current problems and future developments.

Authors:  Ram Gokal
Journal:  J Am Soc Nephrol       Date:  2002-01       Impact factor: 10.121

Review 2.  Pathogenesis and management of malnutrition in chronic peritoneal dialysis patients.

Authors:  N V Dombros
Journal:  Nephrol Dial Transplant       Date:  2001       Impact factor: 5.992

3.  Patient-reported quality of life early in dialysis treatment: effects associated with usual exercise activity.

Authors:  N G Kutner; R Zhang; W M McClellan
Journal:  Nephrol Nurs J       Date:  2000-08       Impact factor: 0.959

4.  Comparison of quality-of-life assessment in Russia and the United States in chronic peritoneal dialysis patients.

Authors:  Peter H Juergensen; Alexander Zemchenkov; Susan Watnick; Susan Finkelstein; Diane Wuerth; Fredric O Finkelstein
Journal:  Adv Perit Dial       Date:  2002

5.  Low-GDP peritoneal dialysis fluid ('balance') has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid.

Authors:  María Auxiliadora Bajo; María Luisa Pérez-Lozano; Patricia Albar-Vizcaino; Gloria del Peso; María-José Castro; Guadalupe Gonzalez-Mateo; Antonio Fernández-Perpén; Abelardo Aguilera; Rafael Sánchez-Villanueva; J Antonio Sánchez-Tomero; Manuel López-Cabrera; Mirjam E Peter; Jutta Passlick-Deetjen; Rafael Selgas
Journal:  Nephrol Dial Transplant       Date:  2010-06-22       Impact factor: 5.992

6.  Optimal peritoneal dialysis for patients from Hong Kong.

Authors:  K N Lai; W K Lo
Journal:  Perit Dial Int       Date:  1999       Impact factor: 1.756

7.  Peritoneal dialysis fluids can alter HSP expression in human peritoneal mesothelial cells.

Authors:  Thorsten O Bender; Michael Böhm; Klaus Kratochwill; Regina Vargha; Andrea Riesenhuber; Janusz Witowski; Achim Jörres; Anders Wieslander; Christoph Aufricht
Journal:  Nephrol Dial Transplant       Date:  2010-08-16       Impact factor: 5.992

8.  Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.

Authors:  Takashi Shimada; Itaru Urakawa; Tamara Isakova; Yuji Yamazaki; Michael Epstein; Katherine Wesseling-Perry; Myles Wolf; Isidro B Salusky; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

9.  Psychosocial and psychiatric morbidity in patients on CAPD.

Authors:  W C Lye; P S Chan; S O Leong; J C van der Straaten
Journal:  Adv Perit Dial       Date:  1997

10.  Depression in hemodialysis patients.

Authors:  G A Hinrichsen; J A Lieberman; S Pollack; H Steinberg
Journal:  Psychosomatics       Date:  1989       Impact factor: 2.386

View more
  1 in total

1.  Peritoneal dialysis treatment for severe lupus nephritis patients complicated with essential organ dysfunction.

Authors:  Yan Zhou; Yusheng Yu; Zheng Tang; Shijun Li; Weixin Hu; Chunlei Luo; Zhihong Liu
Journal:  Exp Ther Med       Date:  2015-10-14       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.